Results & Expectations
    Retatrutide

    Retatrutide Weight Loss by Gender

    Men and women lose weight differently -- different rates, different patterns, different body regions. Here is how gender influences retatrutide results and why percentage matters more than pounds.

    Published: April 3, 202612 min read

    The question "do men lose more weight on retatrutide?" has a nuanced answer. In absolute pounds, typically yes -- men start heavier and have higher metabolic rates. But in percentage terms, the difference narrows substantially. Phase 2 data (Jastreboff et al., NEJM 2023) showed significant weight loss in both men and women, with both groups achieving the transformative results that make retatrutide unique among weight loss medications.

    Data Context

    Gender-stratified results from Phase 2 are limited. Phase 3 trials with larger enrollment will provide more detailed gender-based analysis. Retatrutide is investigational.

    Why Men Often Lose Faster Initially

    Men typically have 10-15% more muscle mass than women at the same body weight. Muscle is metabolically active tissue that burns calories at rest. This higher basal metabolic rate means men start with a larger caloric deficit when appetite is suppressed by the same amount. Additionally, men tend to carry more visceral fat, which is mobilized more readily during weight loss than subcutaneous fat. Finally, men do not experience the monthly hormonal fluctuations that cause water retention variations in premenopausal women.

    Why Percentage Results Converge

    Over the full 48-week treatment period, percentage weight loss between men and women tends to converge. The initial speed advantage men have is offset by several factors: women's bodies become more metabolically efficient as they lose weight, hormonal influences on fat distribution change with significant weight loss, and the appetite-suppressing effects of triple agonism are comparable between genders.

    Gender-Specific Considerations

    For Women

    • Track weight as a 4-week average to smooth out menstrual cycle fluctuations
    • Weight loss may restore ovulatory cycles -- discuss contraception if relevant
    • PCOS symptoms (irregular periods, acne, hirsutism) often improve dramatically with weight loss
    • Bone density monitoring may be appropriate for postmenopausal women losing significant weight

    For Men

    • Testosterone levels typically improve with weight loss, enhancing muscle preservation
    • Sleep apnea resolution rates are particularly high in men who lose 20%+ body weight
    • Erectile dysfunction often improves with weight loss and improved cardiovascular health
    • Higher caloric needs may make protein targets easier to meet despite appetite suppression

    To start your weight loss journey, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. Gender-specific outcomes are estimates. Clinical data from Phase 2 (Jastreboff et al., NEJM 2023). Consult a healthcare provider.

    Effective for Men and Women

    Start today. Semaglutide from $99/mo, tirzepatide from $125/mo.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: February 7, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Really great customer service! Fast shipment.

    Outcome: Fast shipment

    Amy KeithFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    Week-by-week weight loss expectations on retatrutide. Understand the typical trajectory from first injection through 48 weeks, including acceleration phases, plateaus, and realistic weekly targets.

    Retatrutide for women: complete guide covering hormonal considerations, menstrual cycle effects, contraception interactions, PCOS, fertility, menopause, and women-specific weight loss results from cli

    Start your GLP-1 journey — from $99/mo

    Get Started